Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05198934 |
Title索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤（KRAS）p.G12C 突变患者（代码 300） | 阶段
第三阶段
|
Date Added 2022-01-20 |
地点
Alabama, United States
California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States 澳大利亚 法国 德国 希腊 意大利 日本 大韩民国 墨西哥 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05194735 |
Title表达 T 细胞受体 (TCR) 的自体 T 细胞对实体瘤受试者的 I/II 期研究 | 阶段
第 1 阶段
|
Date Added 2022-01-18 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Aldesleukin (IL-2), Neoantigen specific TCR-T cell drug product |
标签
MSS/ MMRp
|
| NCT ID NCT05167409 |
TitleA Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-22 |
地点
Arizona, United States
Colorado, United States New Jersey, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05141721 |
TitleA Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-12-02 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Maryland, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05141474 |
Title评估体外下一代新抗原选择的肿瘤浸润淋巴细胞（TIL）疗法在晚期上皮肿瘤和免疫检查点阻断剂（ICB）耐受性实体瘤中的安全性和耐受性 | 阶段
早期阶段 1
|
Date Added 2021-12-02 |
地点
西班牙
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Interleukin-2, NEXTGEN-TIL, Non-myeloablative Lymphodepletion (NMA-LD) Regimen |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05107674 |
TitleA Study of NX-1607 in Adults With Advanced Malignancies | 阶段
第 1 阶段
|
Date Added 2021-11-04 |
地点
California, United States
Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
NX-1607 |
标签
MSS/ MMRp
|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2021-08-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
标签
MSS/ MMRp
|
| NCT ID NCT04991948 |
Title转移性结直肠癌患者在 CYAD-101 治疗后使用 FOLFOX 预处理的 Pembrolizumab 治疗研究 | 阶段
第 1 阶段
|
Date Added 2021-08-05 |
地点
Florida, United States
比利时 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
CYAD-101, FOLFOX, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04984369 |
TitleHLX208（BRAF V600E 抑制剂）联合西妥昔单抗治疗一线治疗后出现 BRAF V600E 突变的转移性结直肠癌 (mCRC) 的疗效观察 | 阶段
第二阶段
|
Date Added 2021-07-30 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cetuximab Injection [Erbitux], HLX208 |
标签
MSS/ MMRp
|
| NCT ID NCT04973163 |
Title测试不同剂量的 BI 1823911 单独或与其他药物联合用于不同类型的 KRAS 基因突变晚期癌症患者的研究 | 阶段
第 1 阶段
|
Date Added 2021-07-22 |
地点
Texas, United States
比利时 西班牙 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BI 1701963, BI 1823911, Midazolam |
标签
MSS/ MMRp
|
